Exenatide was the first GLP-1 analog approved by the FDA in 2005. It is administered through subcutaneous injection twice daily, before major meals. Exenatide reduces
| Founded year: | Not set |
| Funding rounds: | Not set |
| Total funding amount: | Not set |
| Founded year: | Not set |
| Funding rounds: | Not set |
| Total funding amount: | Not set |